Protara Therapeutics, Inc. TARA
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2014 · data as of November 13, 2026
Protara Therapeutics, Inc. (TARA) is a healthcare company listed in the US with a market value of about $156M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -33%.
About Protara Therapeutics
Protara Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2014. It was profitable in 0 of the last 10 years in our data. Its share count rose by 280% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$57M | -$45M | -$40M | -$66M | -$47M | -$34M | -$8M | -$21M | -$30M | -$29M |
| Free cash flow | -$56M | -$36M | -$38M | -$27M | -$35M | -$24M | -$5M | -$23M | -$22M | -$24M |
| EPS (diluted) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 | $-4.70 | $-3.04 | $-45.80 | $-85.20 | $-68.80 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -25.5% | -22.6% | -46.7% | -48.8% | -22.2% | -13.6% | — | -353.4% | -69.0% | -59.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Protara Therapeutics pay a dividend?
Not currently.
Is Protara Therapeutics a good stock to buy?
We do not give buy or sell advice. Protara Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.